Apixaban's bioavailability is affected by factors like food and gastrointestinal function, posing delivery challenges [1]. Administering the drug in specific dosage forms aims to optimize its absorption [1].
How is Apixaban Delivered?
Apixaban is typically administered orally as a tablet [2]. For patients unable to swallow whole tablets, apixaban can be dispersed in water, apple juice, or dextrose 5% solution and then administered [1]. The dispersed mixture should be consumed promptly, followed by rinsing the container with more liquid and drinking the rinse to ensure complete ingestion [1]. It can also be administered via a nasogastric tube (14 Fr or larger) [1].
What Factors Influence Apixaban Absorption?
The absorption of apixaban is generally rapid, with peak plasma concentrations reached within 2 to 3 hours [1]. However, administration with food does not significantly alter the area under the curve (AUC) of apixaban, suggesting that food does not greatly impact overall exposure [1]. For individuals with severe renal impairment not on dialysis, AUC is increased, and for those on dialysis, AUC is also increased [1]. Hepatic impairment can also affect apixaban exposure [1].
Are There Different Strengths of Apixaban?
Apixaban is available in 2.5 mg and 5 mg oral tablets [3].
When Do Apixaban Patents Expire?
Patent expiry dates for apixaban vary by region and specific patents. Information on patent status and exclusivity can be found on DrugPatentWatch.com [4]. For instance, the original composition of matter patent for apixaban is set to expire, but other patents related to its use and formulation may extend market exclusivity [4].
What Are the Challenges with Apixaban Formulations?
Challenges in apixaban formulation development often revolve around ensuring consistent and predictable bioavailability across different patient populations and administration methods [1]. The need for alternatives for patients with swallowing difficulties highlights the importance of dispersible or liquid formulations, which require careful consideration of drug stability and taste masking [1].
Can Generic Versions of Apixaban Be Developed?
The development of generic apixaban hinges on the expiration of relevant patents [4]. Once primary patents expire, generic manufacturers can seek regulatory approval to market their versions, provided they meet bioequivalence standards [4]. However, secondary patents covering specific methods of use or formulations can influence the timeline for generic market entry [4].
How Does Apixaban Compare to Other Anticoagulants?
Apixaban is a direct oral anticoagulant (DOAC) and is often compared to other DOACs like rivaroxaban and dabigatran, as well as traditional anticoagulants like warfarin [5]. These comparisons typically focus on efficacy, safety profiles (including bleeding risks), dosing regimens, and the need for routine monitoring [5].
What Are the Clinical Trial Results for Apixaban?
Clinical trials have demonstrated apixaban's efficacy in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation and in treating deep vein thrombosis (DVT) and pulmonary embolism (PE) [6]. Studies have also evaluated its use in reducing the risk of recurrent DVT and PE [6].
What Side Effects Are Associated with Apixaban?
The most significant side effect associated with apixaban, like other anticoagulants, is bleeding [1][6]. Other reported side effects include bruising and nausea [1].
---
Sources:
[1] https://www.rxlist.com/eliqiu-drug.htm
[2] https://www.drugbank.ca/drugs/DB06148
[3] https://www. Drugs.com/dosage/apixaban.html
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700304/
[6] https://www.ncbi.nlm.nih.gov/books/NBK542200/